首页> 中文期刊> 《国际病理科学与临床杂志》 >慢性荨麻疹非抗组胺药物治疗进展

慢性荨麻疹非抗组胺药物治疗进展

             

摘要

The first-line therapy for chronic urticaria is the second generation histamine H1 receptor antagonist. However, some patients with chronic refractory urticaria using regular doses of histamine H1 receptor antagonist have no obvious effect. So, we often combine histamine H1 receptor antagonist with non-antihistamine drugs to cure chronic refractory urticaria. According to clinical observation, the curative effect of combination therapy of chronic urticaria is superior to using histamine H1 receptor antagonist alone. The commonly used non antihistamine drugs include leukotriene receptor antagonist, glucocorticoid, tricyclic antidepressants, immunosuppressants, biologics, etc. But the non-antihistamine drugs have more side effects. It is recommended to weigh the pros and cons before using these drugs, and we should also pay attention to monitoring the occurrence of the side effects during using.%慢性荨麻疹的一线治疗药物为第二代组胺H1受体拮抗剂,然而部分慢性难治性荨麻疹患者使用常规剂量组胺H1受体拮抗剂没有明显效果.因此,常联合非抗组胺药治疗慢性难治性荨麻疹.根据临床观察,联合治疗慢性荨麻疹的疗效明显优于单独使用组胺H1受体拮抗剂.常用的非抗组胺药物有白三烯受体拮抗剂、糖皮质激素、三环类抗抑郁药、免疫抑制剂、生物制剂等,但是非抗组胺药物的不良反应较多,建议在使用前权衡利弊,使用过程中还应注意监测不良反应的发生.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号